(MedPage Today) — A federal deadline ending the sale of compounded semaglutide (Ozempic, Wegovy) is now in effect after a similar one for tirzepatide (Mounjaro, Zepbound) passed in March. (U.S. News & World Report)
A patient-delivered lifestyle…
Source link : https://www.medpagetoday.com/endocrinology/generalendocrinology/115774
Author :
Publish date : 2025-05-27 19:34:00
Copyright for syndicated content belongs to the linked Source.
